Obesity, weight loss and conditional cardiovascular risk factors

Obesity Reviews

Volumn 12, Issue 5, 2011, Pages

  Tzotzas, T ^a   Evangelou, P ^b   Kiortsis, D N ^b  

^a PANAGIA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atherosclerosis; Conditional risk factors; Obesity; Weight loss

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; BARIATRIC SURGERY; BODY WEIGHT; CARDIOVASCULAR REFLEX; DIET; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; OBESITY; PARTICLE SIZE; RISK FACTOR; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 79954995455     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2010.00807.x     Document Type: Article

References (83)

1. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290: 932-940.
2. Kullo IJ, Ballantyne CM. Conditional risk factors for atherosclerosis. Mayo Clin Proc 2005; 80: 219-230.
3. Assmann G, Cullen P, Fruchart JC, Greten H, Naruszewicz M, Olsson A, Paoletti R, Riesen W, Stoll M, Tikkanen M, von Eckardstein A. Implications of emerging risk factors for therapeutic intervention. Nutr Metab Cardiovasc Dis 2005; 15: 373-381.
4. U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151: 474-482.
5. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482.
6. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
7. Nguyen XM, Lane J, Smith BR, Nguyen NT. Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J Gastrointest Surg 2009; 13: 1205-1212.
8. Sola E, Vaya A, Simo M, Hernandez-Mijares A, Morillas C, Espana F, Estelles A, Corella D. Fibrinogen, plasma viscosity and blood viscosity in obesity. Relationship with insulin resistance. Clin Hemorheol Microcirc 2007; 37: 309-318.
9. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368-374.
10. Tessari P, Cosma A, Vettore M, Millioni R, Puricelli L, Cogo P, Cecchet D, Carnielli V, Kiwanuka E. Fibrinogen kinetics and protein turnover in obese non-diabetic males: effects of insulin. Diabetes Metab Res Rev 2010; 26: 50-58.
11. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009; 10: 554-563.
12. Ditschuneit HH, Flechtner-Mors M, Adler G. Fibrinogen in obesity before and after weight reduction. Obes Res 1995; 3: 43-48.
13. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998; 52: 329-333.
14. Marckmann P, Sandstrom B, Jespersen J. Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction in dietary fat content. Arterioscler Thromb 1992; 12: 201-205.
15. Pieterse Z, Jerling JC, Oosthuizen W, Kruger HS, Hanekom SM, Smuts CM, Schutte AE. Substitution of high monounsaturated fatty acid avocado for mixed dietary fats during an energy-restricted diet: effects on weight loss, serum lipids, fibrinogen, and vascular function. Nutrition 2005; 21: 67-75.
16. Primrose JN, Davies JA, Prentice CR, Hughes R, Johnston D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-399.
17. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, Richelsen B. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008; 158: 179-187.
18. Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001; 25: 212-218.
19. Devaraj S, Singh U, Human JI. C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009; 20: 182-189.
20. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003; 21: 315-325.
21. Mosca L. C-reactive protein - to screen or not to screen? N Engl J Med 2002; 347: 1615-1617.
22. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab 2009; 296: E1210-E1229.
23. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010; 11: 11-18.
24. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
25. Raitakari M, Ilvonen T, Ahotupa M, Lehtimaki T, Harmoinen A, Suominen P, Elo J, Hartiala J, Raitakari OT. Weight reduction with very-low-caloric diet and endothelial function in overweight adults: role of plasma glucose. Arterioscler Thromb Vasc Biol 2004; 24: 124-128.
26. Due A, Toubro S, Stender S, Skov AR, Astrup A. The effect of diets high in protein or carbohydrate on inflammatory markers in overweight subjects. Diabetes Obes Metab 2005; 7: 223-229.
27. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, McGrory J, Gracely EJ, Rader DJ, Samaha FF. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med 2004; 117: 398-405.
28. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804.
29. Okita K, Nishijima H, Murakami T, Nagai T, Morita N, Yonezawa K, Iizuka K, Kawaguchi H, Kitabatake A. Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004; 24: 1868-1873.
30. Meyer T, Gabriel HH, Ratz M, Muller HJ, Kindermann W. Anaerobic exercise induces moderate acute phase response. Med Sci Sports Exerc 2001; 33: 549-555.
31. Joao Cabrera E, Valezi AC, Delfino VD, Lavado EL, Barbosa DS. Reduction in plasma levels of inflammatory and oxidative stress indicators after Roux-en-Y gastric bypass. Obes Surg 2010; 20: 42-49.
32. Vazquez LA, Pazos F, Berrazueta JR, Fernandez-Escalante C, Garcia-Unzueta MT, Freijanes J, Amado JA. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005; 90: 316-322.
33. Swarbrick MM, Stanhope KL, Austrheim-Smith IT, Van Loan MD, Ali MR, Wolfe BM, Havel PJ. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 2008; 51: 1901-1911.
34. Hsieh CJ, Wang PW, Liu RT, Tung SC, Chien WY, Chen JF, Chen CH, Kuo MC, Hu YH. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005; 67: 78-83.
35. Scanu AM. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. JAMA 1992; 267: 3326-3329.
36. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-2528.
37. Kamstrup PR. Lipoprotein(a) and ischemic heart disease - a causal association? A review. Atherosclerosis 2010; 211: 15-23.
38. Chien KL, Lee YT, Sung FC, Su TC, Hsu HC, Lin RS. Lipoprotein(a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors. Atherosclerosis 1999; 143: 267-273.
39. Akanji AO, al-Shayji IA, Kumar P. Metabolic and anthropometric determinants of serum Lp(a) concentrations and Apo(a) polymorphism in a healthy Arab population. Int J Obes Relat Metab Disord 1999; 23: 855-862.
40. Ditschuneit HH, Flechtner-Mors M, Adler G. Lipoprotein(a) in obesity before and after weight reduction. Nutr Metab Cardiovasc Dis 1996; 32-38.
41. Posadas-Romero C, Hernandez-Ono A, Zamora-Gonzalez J, Cardoso-Saldana G, Yamamoto-Kimura L, Brito-Zurita OR. Differential effects of obesity with and without hyperinsulinemia on plasma lipoprotein(a) concentrations in men. Metabolism 2001; 50: 178-183.
42. Corsetti JP, Sterry JA, Sparks JD, Sparks CE, Weintraub M. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population. Clin Chem 1991; 37: 1191-1195.
43. Muls E, Kempen K, Vansant G, Cobbaert C, Saris W. The effects of weight loss and apolipoprotein E polymorphism on serum lipids, apolipoproteins A-I and B, and lipoprotein(a). Int J Obes Relat Metab Disord 1993; 17: 711-716.
44. Kiortsis DN, Tzotzas T, Giral P, Bruckert E, Beucler I, Valsamides S, Turpin G. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis 2001; 11: 153-157.
45. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson T, Roheim P, Ramakrishnan R, Reed R, Stewart K, Stewart P, Phillips K, Anderson N. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 1998; 18: 441-449.
46. Boman L, Ericson M. Lipoprotein A levels after intestinal bypass operation for morbid obesity. Obes Surg 1997; 7: 125-127.
47. Austin MA, Brunzell JD, Fitch WL, Krauss RM. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990; 10: 520-530.
48. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; 109(23 Suppl 1): III2-7.
49. Magkos F, Mohammed BS, Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int J Obes (Lond) 2008; 32: 1655-1664.
50. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006; 55: 885-891.
51. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnik GR. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 407-419.
52. Goff DC Jr, D'Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005; 54: 264-270.
53. MacLean PS, Vadlamudi S, MacDonald KG, Pories WJ, Houmard JA, Barakat HA. Impact of insulin resistance on lipoprotein subpopulation distribution in lean and morbidly obese nondiabetic women. Metabolism 2000; 49: 285-292.
54. Weiss R, Otvos JD, Flyvbjerg A, Miserez AR, Frystyk J, Sinnreich R, Kark JD. Adiponectin and lipoprotein particle size. Diabetes Care 2009; 32: 1317-1319.
55. Siri-Tarino PW, Williams PT, Fernstrom HS, Rawlings RS, Krauss RM. Reversal of small, dense LDL subclass phenotype by normalization of adiposity. Obesity (Silver Spring) 2009; 17: 1768-1775.
56. Desroches S, Lamarche B. Diet and low-density lipoprotein particle size. Curr Atheroscler Rep 2004; 6: 453-460.
57. Parks EJ, Hellerstein MK. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000; 71: 412-433.
58. Volek JS, Sharman MJ, Gomez AL, DiPasquale C, Roti M, Pumerantz A, Kraemer WJ. Comparison of a very low-carbohydrate and low-fat diet on fasting lipids, LDL subclasses, insulin resistance, and postprandial lipemic responses in overweight women. J Am Coll Nutr 2004; 23: 177-184.
59. Westman EC, Yancy WS, Jr, Olsen MK, Dudley T, Guyton JR. Effect of a low-carbohydrate, ketogenic compared to a low-fat diet on fasting lipoprotein subclasses. Int J Cardiol 2006; 110: 212-216.
60. Kang HS, Gutin B, Barbeau P, Owens S, Lemmon CR, Allison J, Litaker MS, Le NA. Physical training improves insulin resistance syndrome markers in obese adolescents. Med Sci Sports Exerc 2002; 34: 1920-1927.
61. Elosua R, Molina L, Fito M, Arquer A, Sanchez-Quesada JL, Covas MI, Ordonez-Llanos J, Marrugat J. Response of oxidative stress biomarkers to a 16-week aerobic physical activity program, and to acute physical activity, in healthy young men and women. Atherosclerosis 2003; 167: 327-334.
62. Decewicz DJ, Neatrour DM, Burke A, Haberkorn MJ, Patney HL, Vernalis MN, Ellsworth DL. Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. Lipids Health Dis 2009; 8: 26.
63. Manzato E, Zambon S, Zambon A, Digito M, Carraro R, Crepaldi G, Enzi G. Lipoprotein sub-fraction levels and composition in obese subjects before and after gastroplasty. Int J Obes Relat Metab Disord 1992; 16: 573-578.
64. Zambon S, Romanato G, Sartore G, Marin R, Busetto L, Zanoni S, Favretti F, Sergi G, Fiorett P, Manzato E. Bariatric surgery improves atherogenic LDL profile by triglyceride reduction. Obes Surg 2009; 19: 190-195.
65. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 428-437.
66. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1203-1212.
67. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-621.
68. Martos R, Valle M, Morales R, Canete R, Gavilan MI, Sanchez-Margalet V. Hyperhomocysteinemia correlates with insulin resistance and low-grade systemic inflammation in obese prepubertal children. Metabolism 2006; 55: 72-77.
69. Papandreou D, Rousso I, Makedou A, Arvanitidou M, Mavromichalis I. Association of blood pressure, obesity and serum homocysteine levels in healthy children. Acta Paediatr 2007; 96: 1819-1823.
70. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698.
71. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575.
72. Borson-Chazot F, Harthe C, Teboul F, Labrousse F, Gaume C, Guadagnino L, Claustrat B, Berthezene F, Moulin P. Occurrence of hyperhomocysteinemia 1 year after gastroplasty for severe obesity. J Clin Endocrinol Metab 1999; 84: 541-545.
73. Keogh JB, Brinkworth GD, Noakes M, Belobrajdic DP, Buckley JD, Clifton PM. Effects of weight loss from a very-low-carbohydrate diet on endothelial function and markers of cardiovascular disease risk in subjects with abdominal obesity. Am J Clin Nutr 2008; 87: 567-576.
74. Verhoef P, Katan MB. A healthy lifestyle lowers homocysteine, but should we care? Am J Clin Nutr 2004; 79: 713-714.
75. Joubert LM, Manore MM. Exercise, nutrition, and homocysteine. Int J Sport Nutr Exerc Metab 2006; 16: 341-361.
76. Dixon JB, Dixon ME, O'Brien PE. Elevated homocysteine levels with weight loss after Lap-Band surgery: higher folate and vitamin B12 levels required to maintain homocysteine level. Int J Obes Relat Metab Disord 2001; 25: 219-227.
77. Dixon JB, Anderson M, Cameron-Smith D, O'Brien PE. Sustained weight loss in obese subjects has benefits that are independent of attained weight. Obes Res 2004; 12: 1895-1902.
78. Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis 2008; 18: 477-482.
79. Tzotzas T, Dumont L, Triantos A, Karamouzis M, Constantinidis T, Lagrost L. Early decreases in plasma lipid transfer proteins during weight reduction. Obesity (Silver Spring) 2006; 14: 1038-1045.
80. Laimer MW, Engl J, Tschoner A, Kaser S, Ritsch A, Tatarczyk T, Rauchenzauner M, Weiss H, Aigner F, Patsch JR, Ebenbichle CF. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids 2009; 44: 1125-1130.
81. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006; 30: 400-418.
82. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the ATTICA Study. J Am Coll Cardiol 2004; 44: 152-158.
83. Goulet J, Lamarche B, Charest A, Nadeau G, Lapointe A, Desroches S, Lemieux L. Effect of a nutritional intervention promoting the Mediterranean food pattern on electrophoretic characteristics of low-density lipoprotein particles in healthy women from the Quebec City metropolitan area. Br J Nutr 2004; 92: 285-293.